Zobrazeno 1 - 10 of 11 pro vyhledávání: '"Mike Trower"'
1
Akademický článek
Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial
Autor: Sonja Ständer, Andrew Wood, Giuseppe Tonini, Mike Trower, Ajay Duggal, Pamela Guglielmini, David Jackson, Emiliangelo Ratti
Publikováno v: BMJ Open, Vol 10, Iss 2 (2020)
ObjectiveTo evaluate the efficacy of orvepitant (10 or 30 mg given once daily, orally for 4 weeks), a neurokinin-1 receptor antagonist, compared with placebo in reducing the intensity of epidermal growth factor receptor inhibitor (EGFRI)-induced inte
Externí odkaz: https://doaj.org/article/23e261866d8548f4aff8e382753931eb
Zobrazit plný text záznamu
2
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)
Autor: James A. Simon, Richard A. Anderson, Elizabeth Ballantyne, James Bolognese, Cecilia Caetano, Hadine Joffe, Mary Kerr, Nick Panay, Christian Seitz, Susan Seymore, Mike Trower, Lineke Zuurman, Steve Pawsey
Publikováno v: Simon, J A, Anderson, R A, Ballantyne, E, Bolognese, J, Caetano, C, Joffe, H, Kerr, M, Panay, N, Seitz, C, Seymore, S, Trower, M, Zuurman, L & Pawsey, S 2023, ' Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1) ', Menopause . https://doi.org/10.1097/GME.0000000000002138
Objective Neurokinin (NK)-3 and NK-1 receptors have been implicated in the etiology of vasomotor symptoms (VMS) and sleep disturbances associated with menopause. This phase 2b, adaptive, dose-range finding study aimed to assess the efficacy and safet
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc9f531434258a66ce71f536338a9fd7
https://www.pure.ed.ac.uk/ws/files/327901912/Efficacy_and_safety_of_elinzanetant_a_selective.146.pdf
Zobrazit plný text záznamu
3
Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
Autor: Elizabeth Ballantyne, Richard A. Anderson, Mike Trower, Steve Pawsey, Mary Kerr, Hadine Joffe
Publikováno v: Trower, M, Anderson, R, Ballantyne, E, Joffe, H, Kerr, M & Pawsey, S 2020, ' Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized controlled trial ', Menopause . https://doi.org/10.1097/GME.0000000000001500
Menopause (New York, N.y.)
Objectives: To evaluate the safety, pharmacokinetics, and preliminary efficacy of NT-814, a dual neurokinin 1,3 antagonist, in postmenopausal women with vasomotor symptoms (hot flashes). Methods: We completed a double-blind, randomized, placebo-contr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a6fef2fb73abffe9fbb5795bd9a126a
https://doi.org/10.1097/gme.0000000000001500
Zobrazit plný text záznamu
4
Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women
Autor: Elizabeth Ballantyne, Kirsteen Donaldson, Mike Trower, Waljit S. Dhillo, Mary Kerr, Steve Pawsey, Edouard Mills
Publikováno v: The Journal of Clinical Endocrinology and Metabolism
Context The ideal therapy for endometriosis (EM) and uterine fibroids (UFs) would suppress estrogenic drive to the endometrium and myometrium, while minimizing vasomotor symptoms and bone loss associated with current treatments. An integrated neuroki
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c6e43f55466c3707db02fa5cc924297
https://pubmed.ncbi.nlm.nih.gov/33846737
Zobrazit plný text záznamu
6
SUN-LB58 Repeated Once-Daily Administration of the Non-Hormonal Neurokinin 1,3 Receptor Antagonist NT-814 Reduces LH, Estradiol and Progesterone in Healthy Women
Autor: Steve Pawsey, Elizabeth Ballantyne, Kirsteen Donaldson, Mary Kerr, Mike Trower, Waljit S. Dhillo
Publikováno v: Journal of the Endocrine Society
Introduction: Uterine fibroids (UF) affect up to 25% of women and endometriosis (EM) 10% of women worldwide. An ideal therapy would lower estradiol concentrations to reduce hormonal drive to the endometrium and myometrium, but not to the levels which
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21271826bf7b6f7b3c256c8943c47d27
http://europepmc.org/articles/PMC7209475
Zobrazit plný text záznamu
7
OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)
Autor: Steve Pawsey, Mike Trower, Hadine Joffe, Elizabeth Ballantyne, Richard A. Anderson, Susan Seymore, Mary Kerr, James A. Simon
Publikováno v: Journal of the Endocrine Society
Introduction: Vasomotor symptoms (VMS), caused by declining estrogen in menopausal women, are common and debilitating. Hormone therapy is effective in many women but carries risks and may be contraindicated. Biological and clinical evidence shows a m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab427f598ee79dfd3373d55a18248704
https://doi.org/10.1210/jendso/bvaa046.2071
Zobrazit plný text záznamu
10
Monitoring cell response by cluster analysis of a gene expression matrix
Autor: S. Blakemore, C.L. Clayton, Jean E. Crabtree, Phil A. Robinson, J.M. Cox, Philippe Sanseau, D.M. Wallace, F. Falciani, Mike Trower
Publikováno v: Nature Genetics. 23:44-44
We have developed a technology for the identification of genes differentially regulated between biological samples based around the hybridisation of RNA- derived probes onto nylon membranes containing immobilised cDNAs gridded at high density. We use
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b0da39e6755e33b72017533c059cd62
https://doi.org/10.1038/14303
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje